Summary
Global Markets Direct’s, ‘Celltrion, Inc. - Product Pipeline Review - 2016’, provides an overview of the Celltrion, Inc.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Celltrion, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Celltrion, Inc.
- The report provides overview of Celltrion, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Celltrion, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Celltrion, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Celltrion, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Celltrion, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Celltrion, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Celltrion, Inc. Snapshot 5
Celltrion, Inc. Overview 5
Key Information 5
Key Facts 5
Celltrion, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Celltrion, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Celltrion, Inc. - Pipeline Products Glance 11
Celltrion, Inc. - Late Stage Pipeline Products 11
Pre-Registration Products/Combination Treatment Modalities 11
Phase III Products/Combination Treatment Modalities 12
Celltrion, Inc. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Celltrion, Inc. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Celltrion, Inc. - Drug Profiles 16
rituximab biosimilar 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
trastuzumab biosimilar 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
CTP-27 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
adalimumab biosimilar 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
bevacizumab biosimilar 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
cetuximab biosimilar 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
CTP-26 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
etanercept biosimilar 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
palivizumab biosimilar 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
CTP-19 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
CTP-24 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
CTP-25 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Celltrion, Inc. - Pipeline Analysis 30
Celltrion, Inc. - Pipeline Products by Target 30
Celltrion, Inc. - Pipeline Products by Route of Administration 31
Celltrion, Inc. - Pipeline Products by Molecule Type 32
Celltrion, Inc. - Pipeline Products by Mechanism of Action 33
Celltrion, Inc. - Recent Pipeline Updates 34
Celltrion, Inc. - Dormant Projects 36
Celltrion, Inc. - Company Statement 37
Celltrion, Inc. - Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 39
Disclaimer 40
List of Tables
Celltrion, Inc., Key Information 5
Celltrion, Inc., Key Facts 5
Celltrion, Inc. - Pipeline by Indication, 2016 7
Celltrion, Inc. - Pipeline by Stage of Development, 2016 9
Celltrion, Inc. - Monotherapy Products in Pipeline, 2016 10
Celltrion, Inc. - Pre-Registration, 2016 11
Celltrion, Inc. - Phase III, 2016 12
Celltrion, Inc. - Phase II, 2016 13
Celltrion, Inc. - Preclinical, 2016 14
Celltrion, Inc. - Discovery, 2016 15
Celltrion, Inc. - Pipeline by Target, 2016 30
Celltrion, Inc. - Pipeline by Route of Administration, 2016 31
Celltrion, Inc. - Pipeline by Molecule Type, 2016 32
Celltrion, Inc. - Pipeline Products by Mechanism of Action, 2016 33
Celltrion, Inc. - Recent Pipeline Updates, 2016 34
Celltrion, Inc. - Dormant Developmental Projects,2016 36
Celltrion, Inc., Subsidiaries 38
List of Figures
Celltrion, Inc. - Pipeline by Top 10 Indication, 2016 7
Celltrion, Inc. - Pipeline by Stage of Development, 2016 9
Celltrion, Inc. - Monotherapy Products in Pipeline, 2016 10
Celltrion, Inc. - Pipeline by Target, 2016 30
Celltrion, Inc. - Pipeline by Route of Administration, 2016 31
Celltrion, Inc. - Pipeline by Molecule Type, 2016 32
Celltrion, Inc. - Pipeline Products by Mechanism of Action, 2016 33
